力生製藥(002393.SZ)2020年度淨利潤預降60%-100%
格隆匯 12 月 29日丨力生製藥(002393.SZ)公佈,預計2020年度歸屬於上市公司股東的淨利潤0萬元–7525萬元,同比下降60%-100%。業績變動原因如下:
1、受新型冠狀病毒疫情影響,非急症患者去醫院次數減少,進而影響醫院端慢病用藥數量;“4+7”帶量採購影響,藥品價格下降。
2、公司終止23價肺炎球菌多糖疫苗項目,本年將對相關資產計提減值準備約6000萬元,該項減值損失計入公司2020年度合併損益,相應公司2020年度合併報表歸屬於母公司所有者的淨利潤減少約6000萬元,最終數據以會計師事務所審計的財務數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.